E2F1 and prostate carcinoma: Recent studies have found that E2F1 abnormally expresses in a variety of malignant tumors, such as breast cancer [13], prostate cancer [20], ovarian cancer [8], suggesting that it may be an important pathogenic factor in tumorigenesis and development.